cabergoline has been researched along with Menopause in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arlt, W; Ayuk, J; Fountas, A; Gittoes, N; Karavitaki, N; Santharam, S; Tampourlou, M; Toogood, A | 1 |
Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; GarcĂa-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M | 1 |
2 other study(ies) available for cabergoline and Menopause
Article | Year |
---|---|
Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Topics: Adolescent; Adult; Bromocriptine; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Postmenopause; Prolactin; Prolactinoma; Retrospective Studies; Withholding Treatment; Young Adult | 2018 |
Prolactinomas: evolution after menopause.
Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment | 2016 |